Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer

Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic breast cancer by more than six months compared to women treated with a standard therapy of anastrozole alone (47.7 months vs 41.3 months).

The combination therapy also lengthened the median time to disease progression for these patients (15 months vs 13.5 ). Progression-free survival time was the primary endpoint measured in the trial; overall survival time was a secondary endpoint.

"The combination offers a new standard for first-line treatment of postmenopausal women with hormone receptor-positive ," says lead investigator on the study Rita Mehta, M.D., of the University of California, Irvine Medical Center. "It has been many years since these patients have seen a new treatment that can significantly extend their overall survival time."

(Arimidex) and fulvestrant (Faslodex), the anti-estrogen drugs included in the SWOG S0226 trial, are both already used in treating breast cancer, though not in combination. Anastrozole suppresses the body's production of tumor-promoting estrogen, while fulvestrant not only blocks the receptors that estrogen uses to drive to grow and reproduce, but also accelerates the degradation of these receptors. Mehta and her colleagues hypothesized that these two different modes of action together could make the combination more effective than either alone against hormone receptor-positive breast cancer, the subtype seen in more than one half of all cases of breast cancer.

The paper also reports that 41 percent of patients on the anastrozole-only arm switched to fulvestrant treatment after their disease progressed on anastrozole, suggesting that combined use of the two agents rather than the sequential use underlies the impressive seen in the study.

Earlier results of the trial, which enrolled 707 postmenopausal patients at 73 U.S. institutions, were presented at a professional meeting in December 2012. The article reports additional data.

The researchers note that they saw improvement in survival in spite of the fact that the dose of fulvestrant used in the trial – 250 mg monthly – was only half of what the accepted standard is today, and in spite of the fact that the control arm performed better than projected in the design of the study. They recommend that future clinical trials compare the combination of high-dose fulvestrant and an aromatase inhibitor such as anastrozole against each of the drugs alone.

More information: Mehta RS, Barlow WE, Albain KS, et al. "Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer." New England Journal of Medicine 367(5): 37-46, 2012.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Blood biomarker may detect lung cancer

9 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

ACG: Recent increase in incidence of young-onset CRC

Oct 20, 2014

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments